Menu
  • Join
  • Login
  • Contact
 

Search abstracts


COMBINATION OF NAB-PACLITAXEL WITH TRASTUZUMAB AS NEOADJUVANT CHEMOTHERAPY FOR HER2-POSITIVE BREAST CANCER PATIENTS: EXPERIENCE FROM A SINGLE CENTER

  • At: 2015 FIP Congress in Düsseldorf (Germany)
  • Type: Poster
  • By: LI, Tingting (Guangdong General Hospital; Sun Yat-sen University, Department of Pharmacy, Guangzhou, China)
  • Co-author(s): Tingting Li
  • Abstract:

    Anthracycline-based neoadjuvant regimens are widely used for human epidermal growth factor receptor 2 (Her2)-positive breast cancer, which can lead to cardiac toxicity. In order to minimize this side effect, researchers begin to explore the anthracycline-free regimens. Attention was paid to the taxane-based ones.

    From July 2009 to June 2014,

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses